Need Help?

Dataset GBM 2022

The cellular origin and differentiation status of glioblastoma by scRNA-seq

Request Access


1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines ( ) and the Toronto Statement ( This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) ( ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) ( ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify THIS TEAM IN KAROLINSKA INS. within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify THIS TEAM IN KAROLINSKA INS. prior to any significant changes to the protocol for the Project. 14. The User Institution will notify THIS TEAM IN KAROLINSKA INS. as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. THIS TEAM IN KAROLINSKA INS. may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than THIS TEAM IN KAROLINSKA INS.. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001006236 Other
ID File Type Size Located in
EGAF00006158531 fq.gz 925.8 MB
EGAF00006158532 fq.gz 704.9 MB
EGAF00006158533 fq.gz 1.0 GB
EGAF00006158534 fq.gz 852.2 MB
EGAF00006158535 fq.gz 986.9 MB
EGAF00006158536 fq.gz 431.5 MB
EGAF00006158537 fq.gz 812.7 MB
EGAF00006158538 fq.gz 537.5 MB
EGAF00006158539 fq.gz 1.5 GB
EGAF00006158540 fq.gz 1.1 GB
EGAF00006158541 fq.gz 2.4 GB
EGAF00006158542 fq.gz 1.2 GB
EGAF00006158543 fq.gz 912.1 MB
EGAF00006158544 fq.gz 497.3 MB
EGAF00006158545 fq.gz 1.4 GB
EGAF00006158546 fq.gz 637.7 MB
EGAF00006158547 fq.gz 1.1 GB
EGAF00006158548 fq.gz 811.9 MB
EGAF00006158549 fq.gz 1.0 GB
EGAF00006158550 fq.gz 960.1 MB
EGAF00006158551 fq.gz 790.0 MB
EGAF00006158552 fq.gz 761.7 MB
EGAF00006158553 fastq.gz 1.4 GB
EGAF00006158554 fastq.gz 1.6 GB
EGAF00006158555 fastq.gz 1.4 GB
EGAF00006158556 fastq.gz 1.6 GB
EGAF00006158557 fq.gz 572.5 MB
EGAF00006158558 fastq.gz 1.4 GB
EGAF00006158559 fastq.gz 1.7 GB
EGAF00006158560 fastq.gz 798.6 MB
EGAF00006158561 fastq.gz 1.0 GB
EGAF00006158562 fq.gz 960.7 MB
EGAF00006158563 fq.gz 1.5 GB
EGAF00006158564 fq.gz 1.1 GB
EGAF00006158565 fq.gz 880.3 MB
EGAF00006158566 fq.gz 679.5 MB
EGAF00006158567 fq.gz 1.2 GB
EGAF00006158568 fq.gz 1.2 GB
EGAF00006158569 fq.gz 856.7 MB
EGAF00006158570 fq.gz 392.7 MB
EGAF00006158571 fq.gz 1.5 GB
EGAF00006158572 fq.gz 1.1 GB
EGAF00006158573 fq.gz 914.2 MB
EGAF00006158574 fq.gz 845.3 MB
EGAF00006158575 fq.gz 747.0 MB
EGAF00006158576 fq.gz 1.7 GB
EGAF00006158577 fq.gz 2.0 GB
EGAF00006158578 fq.gz 912.1 MB
EGAF00006158579 fq.gz 786.4 MB
EGAF00006158580 fq.gz 946.0 MB
EGAF00006158581 fq.gz 1.2 GB
EGAF00006158582 fq.gz 977.8 MB
EGAF00006158583 fq.gz 980.6 MB
EGAF00006158584 fq.gz 2.2 GB
EGAF00006158585 fq.gz 1.1 GB
EGAF00006158586 fq.gz 794.8 MB
EGAF00006158587 fq.gz 876.6 MB
EGAF00006158588 fastq.gz 1.4 GB
EGAF00006158589 fastq.gz 1.6 GB
EGAF00006158590 fq.gz 1.0 GB
EGAF00006158591 fq.gz 1.1 GB
EGAF00006158592 fq.gz 745.1 MB
EGAF00006158593 fq.gz 778.0 MB
EGAF00006158594 fq.gz 1.0 GB
EGAF00006158595 fq.gz 1.0 GB
EGAF00006158596 fq.gz 912.1 MB
EGAF00006158597 fq.gz 787.3 MB
EGAF00006158598 fq.gz 716.2 MB
EGAF00006158599 fq.gz 577.6 MB
EGAF00006158600 fq.gz 692.3 MB
EGAF00006158601 fq.gz 1.1 GB
EGAF00006158602 fq.gz 658.8 MB
EGAF00006158603 fq.gz 482.0 MB
EGAF00006158604 fq.gz 833.3 MB
EGAF00006158605 fq.gz 1.4 GB
EGAF00006158606 fastq.gz 805.7 MB
EGAF00006158607 fastq.gz 1.1 GB
EGAF00006158608 fq.gz 877.4 MB
EGAF00006158609 fq.gz 1.2 GB
EGAF00006158610 fq.gz 2.9 GB
80 Files (84.6 GB)